NKTR,Nektar Therapeutics | Healthcare

Healthcare

NKTR

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Nektar TherapeuticsNKTR

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer.

It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F.

Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Latest News >

VF Unveils Medium-Term Financial Targets

Nov 3, 2024

10:43 AM EDT, 10/30/2024 (MT Newswires) -- VF (VFC) unveiled Wednesday its medium-term financial targets, including an adjusted operating margin of at least 10% by fiscal 2028. The company also said it aims for at least 55% adjusted gross margin, adjusted selling, general, and administrative expenses as a percentage of revenue of 45% or lower, and a net leverage of...

US cracks down on Russia sanctions evasion in fresh action

Nov 3, 2024

* US imposes sanctions on nearly 400 entities and individuals * Action sends serious message that the US committed to countering evasion, official says * Sanctions target entities, individuals in China, India, Turkey and elsewhere By Daphne Psaledakis and Simon Lewis WASHINGTON, Oct 30 (Reuters) - The United States on Wednesday imposed curbs on hundreds of targets in fresh action...

US Treasury keeps auction sizes through January 2025, announces $125 billion refunding

Nov 3, 2024

NEW YORK (Reuters) - The U.S. Treasury Department said on Wednesday it does not anticipate increasing auction sizes for U.S. notes and bonds for at least the next several quarters, in line with expectations, as it announced quarterly refunding of $125 billion from November 2024 to January 2025. The refunding is intended to raise new cash of $8.6 billion from...

Trane Technologies Delivers Strong Q3: Revenue And EPS Outpace Expectations Amid Rising Demand

Nov 3, 2024

Trane Technologies plc ( TT ) shares are trading higher after the company reported third-quarter financial results and raised its FY24 guidance. Revenues grew 11% year-over-year to $5.44 billion, surpassing the consensus of $5.32 billion. Bookings increased 5% to $5.213 billion in the quarter. Enterprise reported an 11% increase in both revenues and organic revenues. The backlog totaled $7.2 billion, versus $6.9 billion at year-end 2023. Adjusted EBITDA rose 18% to $1.127 billion, with...